Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Hisamitsu, Banyu codevelop new hypolipidemic agent entering phase II

Nov. 3, 1998

Positive pivotal trial results for enzyme replacement therapy to be submitted with BLA

Nov. 2, 1998

Inhibition of ceramide glucosyltransferase as a novel therapeutic target

Nov. 2, 1998

PIXY-321 performs favorably in children; compound unfortunately no longer in development

Nov. 2, 1998

Selective, nonpeptide Y1 receptor antagonist reduces NPY-mediated food intake in rats

Nov. 2, 1998

HMR presents new agents for lipid disorders

Nov. 2, 1998

Licensing opportunity from the NIH: technology for enhancing embryo implantation

Nov. 2, 1998

BioStratum's Pyridorin effective for diabetic nephropathy

Oct. 30, 1998

Oral insulin formulation developed at Generex headed for U.S. clinical trials

Oct. 30, 1998

Novel vitamin D compounds claimed for use in bone disorders and psoriasis

Oct. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...